Alejandro Berlin

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/3296090/alejandro-berlin-publications-by-year.pdf
Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

121 papers	2,043 citations	19 h-index	43 g-index
129 ext. papers	2,925 ext. citations	5.6 avg, IF	4.44 L-index

#	Paper	IF	Citations
121	Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer: A Patient-Level Data Analysis of 3 Cohorts.. *JAMA Oncology*, **2022**,	13.4	2
120	The Use of Virtual Care in Patients with Hematologic Malignancies: A Scoping Review.. *Current Oncology*, **2022**, 29, 892-900	2.8	2
119	Subpathologies and genomic classifier for treatment individualization of post-prostatectomy radiotherapy. *Urologic Oncology: Seminars and Original Investigations*, **2022**, 40, 5.e1-5.e13	2.8	
118	Dosimetric comparison of MR-guided adaptive IMRT versus 3DOF-VMAT for prostate stereotactic radiotherapy.. *Technical Innovations and Patient Support in Radiation Oncology*, **2022**, 21, 64-70	1.9	
117	Low-Grade Prostate Cancer: Time to Stop Calling It Cancer.. *Journal of Clinical Oncology*, **2022**, JCO2200123	12.3	6
116	TNM Staging of Prostate Cancer: Challenges in Securing a Globally Applicable Classification.. *European Urology*, **2022**,	10.2	
115	The Suggested Unique Association Between the Various Statin Subgroups and Prostate Cancer. *European Urology Focus*, **2021**, 7, 537-545	5.1	5
114	Clinical-genomic Characterization Unveils More Aggressive Disease Features in Elderly Prostate Cancer Patients with Low-grade Disease. *European Urology Focus*, **2021**, 7, 797-806	5.1	
113	Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer.. *JAMA Network Open*, **2021**, 4, e2138550	10.4	3
112	The Use of Virtual Care in Patients with Hematologic Malignancies - a Scoping Review. *Blood*, **2021**, 138, 1933-1933	2.2	
111	Virtual Care during the COVID-19 Pandemic Among Patients with Hematologic Malignancies - a Princess Margaret Cancer Centre Experience. *Blood*, **2021**, 138, 838-838	2.2	
110	Creating patient-centered radiology reports to empower patients undergoing prostate magnetic resonance imaging. *Canadian Urological Association Journal*, **2021**, 15, 108-113	1.2	2
109	COVID-19 and patients with cancer: Investigating treatment impact, information sources, and COVID-19-related knowledge, attitudes, and practices. *Cancer*, **2021**,	6.4	1
108	Salvage lymph node dissection for prostate-specific membrane antigen (PSMA) positron emission tomography (PET)-identified oligometastatic disease. *Canadian Urological Association Journal*, **2021**, 15, E545-E552	1.2	0
107	Virtual care for prostate cancer survivorship: protocol for an evaluation of a nurse-led algorithm-enhanced virtual clinic implemented at five cancer centres across Canada. *BMJ Open*, **2021**, 11, e045806	3	1
106	Implementation and Outcomes of Virtual Care Across a Tertiary Cancer Center During COVID-19. *JAMA Oncology*, **2021**, 7, 597-602	13.4	23
105	Detection of clinically significant prostate cancer with F-DCFPyL PET/multiparametric MR. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 48, 3702-3711	8.8	2

104	Deep learning for whole-body medical image generation. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 48, 3817-3826	8.8	5
103	Impact of EGFR mutation on outcomes following SRS for brain metastases in non-small cell lung cancer. *Lung Cancer*, **2021**, 155, 34-39	5.9	1
102	Biorepositories and Databanks for the Development of Novel Biomarkers for Genitourinary Cancer Prevention and Management. *European Urology Focus*, **2021**, 7, 513-521	5.1	
101	Clinical integration of machine learning for curative-intent radiation treatment of patients with prostate cancer. *Nature Medicine*, **2021**, 27, 999-1005	50.5	18
100	Characterization and management of NMIBC recurrences after TMT: a matched cohort analysis. *Urologic Oncology: Seminars and Original Investigations*, **2021**, 39, 835.e1-835.e7	2.8	0
99	Multispecialty Enterprise Imaging Workgroup Consensus on Interactive Multimedia Reporting Current State and Road to the Future: HIMSS-SIIM Collaborative White Paper. *Journal of Digital Imaging*, **2021**, 34, 495-522	5.3	1
98	Can post-treatment free PSA ratio be used to predict adverse outcomes in recurrent prostate cancer?. *BJU International*, **2021**, 127, 654-664	5.6	1
97	The suggested chemopreventive association of metformin with prostate cancer in diabetic patients. *Urologic Oncology: Seminars and Original Investigations*, **2021**, 39, 191.e17-191.e24	2.8	
96	A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer. *European Urology*, **2021**, 79, 374-383	10.2	28
95	Utilization of Salvage and Systemic Therapies for Recurrent Prostate Cancer as a Result of F-DCFPyL PET/CT Restaging. *Advances in Radiation Oncology*, **2021**, 6, 100553	3.3	4
94	Is there an association between a history of military service and cancer diagnosis? Results from a US national-level study of self-reported outcomes. *Cancer Causes and Control*, **2021**, 32, 47-55	2.8	0
93	Single-cell analysis reveals transcriptomic remodellings in distinct cell types that contribute to human prostate cancer progression. *Nature Cell Biology*, **2021**, 23, 87-98	23.4	53
92	Clinicopathologic and Treatment Features of Long-Term Surviving Brain Metastasis Patients. *Current Oncology*, **2021**, 28, 549-559	2.8	2
91	The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited. *European Urology*, **2021**, 80, 632-640	10.2	14
90	Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features. *JAMA Network Open*, **2021**, 4, e2115312	10.4	1
89	Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer. *European Urology*, **2021**, 80, 142-146	10.2	3
88	Practical considerations for prostate hypofractionation in the developing world. *Nature Reviews Urology*, **2021**, 18, 669-685	5.5	3
87	F-DCFPyL (PSMA) PET in the Management of Men with Biochemical Failure after Primary Therapy: Initial Clinical Experience of an Academic Cancer Center. *Current Oncology*, **2021**, 28, 3251-3258	2.8	0

86	Radiation Dose Rate, Biologically Effective Dose, and Tumor Characteristics on Local Control and Toxicity After Radiosurgery for Acoustic Neuromas. *World Neurosurgery*, **2021**, 152, e512-e522	2.1	1
85	Reply to Wei Liu, Katherine Zukotynski, and Glenn Bauman's Letter to the Editor re: Rachel M. Glicksman, Ur Metser, Douglass Vines, et al. Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis. *Eur Urol* 2021;80:374-82. *European Urology*, **2021**, 80, e79-e80	10.2	0
84	Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis. *European Urology*, **2021**, 80, 374-382	10.2	7
83	Sexual function and rehabilitation after radiation therapy for prostate cancer: a review. *International Journal of Impotence Research*, **2021**, 33, 410-417	2.3	2
82	[F]DCFPyL PET-MRI/CT for unveiling a molecularly defined oligorecurrent prostate cancer state amenable for curative-intent ablative therapy: study protocol for a phase II trial. *BMJ Open*, **2020**, 10, e035959	3	3
81	Psychological distress associated with active surveillance in patients younger than 70 with a small renal mass. *Urologic Oncology: Seminars and Original Investigations*, **2020**, 38, 603.e17-603.e25	2.8	8
80	Use of combined androgen deprivation therapy with postoperative radiation treatment for prostate cancer: Impact of randomized trials on clinical practice. *Urologic Oncology: Seminars and Original Investigations*, **2020**, 38, 848.e1-848.e7	2.8	3
79	Transitioning to a New Normal in the Post-COVID Era. *Current Oncology Reports*, **2020**, 22, 73	6.3	6
78	Canadian experience of neoadjuvant chemotherapy on bladder recurrences in patients managed with trimodal therapy for muscle-invasive bladder cancer. *Canadian Urological Association Journal*, **2020**, 14, 404-410	1.2	1
77	Predictors of prostate-specific antigen testing in men aged ≥55 years: A cross-sectional study based on patient-reported outcomes. *International Journal of Urology*, **2020**, 27, 711-718	2.3	2
76	F-DCFPyL PET/CT in Patients with Subclinical Recurrence of Prostate Cancer: Effect of Lesion Size, Smoothing Filter, and Partial-Volume Correction on PROMISE Criteria. *Journal of Nuclear Medicine*, **2020**, 61, 1615-1620	8.9	2
75	Genomic Strategies to Personalize Use of Androgen Deprivation Therapy With Radiotherapy. *Cancer Journal (Sudbury, Mass.)*, **2020**, 26, 13-20	2.2	0
74	Performance of clinicopathologic models in men with high risk localized prostate cancer: impact of a 22-gene genomic classifier. *Prostate Cancer and Prostatic Diseases*, **2020**, 23, 646-653	6.2	6
73	Primary analysis of a phase II study of metastasis-directed ablative therapy to PSMA (18F-DCFPyL) PET-MR/CT defined oligorecurrent prostate cancer.. *Journal of Clinical Oncology*, **2020**, 38, 5553-5553	2.2	1
72	Comparing characteristics and outcomes of cancer to non-cancer patients admitted to general internal medicine (GIM).. *Journal of Clinical Oncology*, **2020**, 38, 21-21	2.2	
71	Tumor-targeted dose escalation for localized prostate cancer using MR-guided HDR brachytherapy (HDR) or integrated VMAT (IB-VMAT) boost: Dosimetry, toxicity and health related quality of life. *Radiotherapy and Oncology*, **2020**, 149, 240-245	5.3	5
70	A Phase II Study of Neoadjuvant Stereotactic Radiosurgery for Large Brain Metastases: Clinical Trial Protocol. *Neurosurgery*, **2020**, 87, 403-407	3.2	5
69	Stereotactic Ablative Radiotherapy for the Management of Spinal Metastases: A Review. *JAMA Oncology*, **2020**, 6, 567-577	13.4	20

68	Gender-based psychological and physical distress differences in patients diagnosed with non-metastatic renal cell carcinoma. *World Journal of Urology*, **2020**, 38, 2547-2554	4	8
67	A Prospective Study of 18F-DCFPyL PSMA PET/CT Restaging in Recurrent Prostate Cancer following Primary External Beam Radiotherapy or Brachytherapy. *International Journal of Radiation Oncology Biology Physics*, **2020**, 106, 546-555	4	18
66	Neurological Death is Common in Patients With EGFR Mutant Non-Small Cell Lung Cancer Diagnosed With Brain Metastases. *Advances in Radiation Oncology*, **2020**, 5, 350-357	3.3	5
65	Salvage radical prostatectomy following focal therapy: functional and oncological outcomes. *BJU International*, **2020**, 125, 525-530	5.6	16
64	Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate. *JAMA Oncology*, **2020**, 6, 1912-1920	13.4	15
63	The deleterious association between proton pump inhibitors and prostate cancer-specific mortality - a population-based cohort study. *Prostate Cancer and Prostatic Diseases*, **2020**, 23, 622-629	6.2	1
62	Salvage Radiotherapy Following Partial Gland Ablation for Prostate Cancer: Functional and Oncological Outcomes. *European Urology Open Science*, **2020**, 21, 1-4	0.9	1
61	Current topics in radiotherapy for genitourinary cancers: Consensus statements of the Genitourinary Radiation Oncologists of Canada. *Canadian Urological Association Journal*, **2020**, 14, E588-E593	1.2	0
60	The reality of virtual care: Implications for cancer care beyond the pandemic. *Healthcare*, **2020**, 8, 100480	1.8	6
59	Virtual care models for cancer survivorship. *Npj Digital Medicine*, **2020**, 3, 113	15.7	12
58	Determining the Impact of Spatial Heterogeneity on Genomic Prognostic Biomarkers for Localized Prostate Cancer. *European Urology Oncology*, **2020**,	6.7	6
57	Hyperbaric Oxygen for Radiation Necrosis of the Brain. *Canadian Journal of Neurological Sciences*, **2020**, 47, 92-99	1	9
56	ONECUT2 is a driver of neuroendocrine prostate cancer. *Nature Communications*, **2019**, 10, 278	17.4	72
55	Dose to the bladder neck in MRI-guided high-dose-rate prostate brachytherapy: Impact on acute urinary toxicity and health-related quality of life. *Brachytherapy*, **2019**, 18, 477-483	2.4	3
54	The current state of randomized clinical trial evidence for prostate brachytherapy. *Urologic Oncology: Seminars and Original Investigations*, **2019**, 37, 599-610	2.8	6
53	Cognitive rehabilitation for executive dysfunction in brain tumor patients: a pilot randomized controlled trial. *Journal of Neuro-Oncology*, **2019**, 142, 565-575	4.8	28
52	A Phase 1 Pilot Study of Preoperative Radiation Therapy for Prostate Cancer: Long-Term Toxicity and Oncologic Outcomes. *International Journal of Radiation Oncology Biology Physics*, **2019**, 104, 61-66	4	3
51	Extraprostatic Extension in Core Biopsies Epitomizes High-risk but Locally Treatable Prostate Cancer. *European Urology Oncology*, **2019**, 2, 88-96	6.7	3

50	Impact of high dose volumetric CT on PTV margin reduction in VMAT prostate radiotherapy. *Physics in Medicine and Biology*, **2019**, 64, 065017	3.8	1
49	Significance of treatment response when managing patients with primary central nervous system lymphoma. *Leukemia and Lymphoma*, **2019**, 60, 349-357	1.9	2
48	Age Differences in Patient-reported Psychological and Physical Distress Symptoms in Bladder Cancer Patients - A Cross Sectional Study. *Urology*, **2019**, 134, 154-162	1.6	4
47	International Multicenter Validation of an Intermediate Risk Subclassification of Prostate Cancer Managed with Radical Treatment without Hormone Therapy. *Journal of Urology*, **2019**, 201, 284-291	2.5	10
46	Case series illustrating the synergistic use of hydrogel spacer and MR-guidance to increase the radiotherapeutic index for localized prostate cancer. *Technical Innovations and Patient Support in Radiation Oncology*, **2019**, 11, 22-25	1.9	2
45	Genomic Classifier for Guiding Treatment of Intermediate-Risk Prostate Cancers to Dose-Escalated Image Guided Radiation Therapy Without Hormone Therapy. *International Journal of Radiation Oncology Biology Physics*, **2019**, 103, 84-91	4	20
44	Quantitative assessment of dynamic F-flumethycholine PET and dynamic contrast enhanced MRI in high risk prostate cancer. *British Journal of Radiology*, **2019**, 92, 20180568	3.4	
43	Radiosurgery and risk of intracranial malignancies: more research needed. *Lancet Oncology, The*, **2019**, 20, 17-18	21.7	0
42	Changes in apparent diffusion coefficient radiomics features during dose-painted radiotherapy and high dose rate brachytherapy for prostate cancer. *Physics and Imaging in Radiation Oncology*, **2019**, 9, 1-6	3.1	7
41	Neoadjuvant Chemotherapy Before Bladder-Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle-Invasive Bladder Cancer. *Clinical Genitourinary Cancer*, **2019**, 17, 38-45	3.3	18
40	Outcomes following stereotactic radiosurgery for small to medium-sized brain metastases are exceptionally dependent upon tumor size and prescribed dose. *Neuro-Oncology*, **2019**, 21, 242-251	1	18
39	F-Fluorocholine PET Whole-Body MRI in the Staging of High-Risk Prostate Cancer. *American Journal of Roentgenology*, **2018**, 210, 635-640	5.4	10
38	Curative Radiation Therapy at Time of Progression Under Active Surveillance Compared With Up-front Radical Radiation Therapy for Prostate Cancer. *International Journal of Radiation Oncology Biology Physics*, **2018**, 100, 702-709	4	1
37	Management and Outcomes in the Oldest-Old Population with Glioblastoma. *Canadian Journal of Neurological Sciences*, **2018**, 45, 199-205	1	5
36	The relationship of study and authorship characteristics on trial sponsorship and self-reported conflicts of interest among neuro-oncology clinical trials. *Journal of Neuro-Oncology*, **2018**, 139, 195-203	4.8	4
35	Magnetic Resonance Imaging-guided Brachytherapy Re-irradiation for Isolated Local Recurrence of Soft Tissue Sarcoma. *Cureus*, **2018**, 10, e2457	1.2	4
34	Funding source, conflict of interest and positive conclusions in neuro-oncology clinical trials. *Journal of Neuro-Oncology*, **2018**, 136, 585-593	4.8	4
33	Dosimetric impact of intrafraction changes in MR-guided high-dose-rate (HDR) brachytherapy for prostate cancer. *Brachytherapy*, **2018**, 17, 59-67	2.4	3

32	Magnetic resonance imaging-guided functional anatomy approach to prostate brachytherapy. *Brachytherapy*, **2017**, 16, 698-714	2.4	7
31	Genomic hallmarks of localized, non-indolent prostate cancer. *Nature*, **2017**, 541, 359-364	50.4	320
30	Challenges and opportunities in primary CNS lymphoma: A systematic review. *Radiotherapy and Oncology*, **2017**, 122, 352-361	5.3	29
29	Significant tumor shift in patients treated with stereotactic radiosurgery for brain metastasis. *Clinical and Translational Radiation Oncology*, **2017**, 2, 23-28	4.6	9
28	Improved outcomes with dose escalation in localized prostate cancer treated with precision image-guided radiotherapy. *Radiotherapy and Oncology*, **2017**, 123, 459-465	5.3	10
27	A Prostate Cancer "Nimbosus": Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies. *European Urology*, **2017**, 72, 665-674	10.2	98
26	Dosimetric feasibility of ablative dose escalated focal monotherapy with MRI-guided high-dose-rate (HDR) brachytherapy for prostate cancer. *Radiotherapy and Oncology*, **2017**, 122, 103-108	5.3	8
25	Use of hydrogel spacer for improved rectal dose-sparing in patients undergoing radical radiotherapy for localized prostate cancer: First Canadian experience. *Canadian Urological Association Journal*, **2017**, 11, 373-375	1.2	1
24	Evaluation of high dose volumetric CT to reduce inter-observer delineation variability and PTV margins for prostate cancer radiotherapy. *Radiotherapy and Oncology*, **2017**, 125, 118-123	5.3	13
23	Stereotactic ablative radiotherapy with targeted MRI-defined gross tumor dose escalation for prostate cancer: dosimetric feasibility and interfraction robustness. *Journal of Radiation Oncology*, **2017**, 6, 397-404	0.7	
22	An integrated multidisciplinary algorithm for the management of spinal metastases: an International Spine Oncology Consortium report. *Lancet Oncology, The*, **2017**, 18, e720-e730	21.7	137
21	Prognostic role of Ki-67 score in localized prostate cancer: A systematic review and meta-analysis. *Urologic Oncology: Seminars and Original Investigations*, **2017**, 35, 499-506	2.8	35
20	The effect of bowel preparation regime on interfraction rectal filling variation during image guided radiotherapy for prostate cancer. *Radiation Oncology*, **2017**, 12, 50	4.2	4
19	Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate Tumors. *European Urology*, **2017**, 72, 22-31	10.2	28
18	Long-term outcomes of a phase II trial of moderate hypofractionated image-guided intensity modulated radiotherapy (IG-IMRT) for localized prostate cancer. *Radiotherapy and Oncology*, **2017**, 122, 93-98	5.3	17
17	Tumour-Targeted Treatment Intensification for Prostate Cancer Using Magnetic Resonance Imaging Guidance. *Journal of Medical Imaging and Radiation Sciences*, **2017**, 48, 336-342	1.4	1
16	Oncologic outcomes of radiation therapy following active surveillance for low- and intermediate-risk localized prostate cancer.. *Journal of Clinical Oncology*, **2017**, 35, 42-42	2.2	
15	Permanent seed brachytherapy for low risk prostate cancer, long term outcome, and urinary toxicity.. *Journal of Clinical Oncology*, **2017**, 35, 66-66	2.2	

14	Liver Failure After Abdominal Irradiation: Identifying the Right Suspects. *Journal of Clinical Oncology*, **2016**, 34, e80-3	2.2	1
13	Lessons learned using an MRI-only workflow during high-dose-rate brachytherapy for prostate cancer. *Brachytherapy*, **2016**, 15, 147-55	2.4	23
12	Gaps between Evidence and Practice in Postoperative Radiotherapy for Prostate Cancer: Focus on Toxicities and the Effects on Health-Related Quality of Life. *Frontiers in Oncology*, **2016**, 6, 70	5.3	9
11	Role of radiotherapy in the chemotherapy-containing multidisciplinary management of patients with resected pancreatic adenocarcinoma. *Strahlentherapie Und Onkologie*, **2015**, 191, 17-25	4.3	1
10	Phase 2 trial of guideline-based postoperative image guided intensity modulated radiation therapy for prostate cancer: Toxicity, biochemical, and patient-reported health-related quality-of-life outcomes. *Practical Radiation Oncology*, **2015**, 5, e473-e482	2.8	17
9	Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine in prostate cancer. *Urologic Oncology: Seminars and Original Investigations*, **2015**, 33, 85-94	2.8	89
8	Spatial genomic heterogeneity within localized, multifocal prostate cancer. *Nature Genetics*, **2015**, 47, 736-45	36.3	306
7	Prostate Cancer Genomics as a Driver of Personalized Medicine **2014**, 233-245		1
6	Prostate cancer screening characteristics in men with BRCA1/2 mutations attending a high-risk prevention clinic. *Canadian Urological Association Journal*, **2014**, 8, E783-8	1.2	6
5	Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. *Lancet Oncology, The*, **2014**, 15, 1521-1532	21.7	218
4	Prognostic utility of cell cycle progession score in men with prostate cancer after primary external beam radiation therapy. In regard to Freedland et al. *International Journal of Radiation Oncology Biology Physics*, **2014**, 88, 237-40	4	4
3	NBN gain is predictive for adverse outcome following image-guided radiotherapy for localized prostate cancer. *Oncotarget*, **2014**, 5, 11081-90	3.3	25
2	Using NBN to predict biochemical relapse following image-guided radiotherapy (IGRT) for intermediate-risk prostate cancer (IR-PCa).. *Journal of Clinical Oncology*, **2014**, 32, 26-26	2.2	
1	Mismatch repair gene expression and genetic instability in testicular germ cell tumor. *Cancer Biology and Therapy*, **2004**, 3, 977-82	4.6	47